<DOC>
	<DOC>NCT00731679</DOC>
	<brief_summary>To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.</brief_summary>
	<brief_title>Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Confirmed IBS diagnosis per Rome II for diagnosis of IBS. Colonoscopy within 2 years as part of IBS diagnostic evaluation. Has active symptoms of nonconstipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency. Symptoms of constipation. History of other gastrointestinal diseases. Type 1 or 2 diabetes. Lactose intolerance not controlled by lactosefree diet.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>IBS</keyword>
	<keyword>Abdominal pain</keyword>
	<keyword>Bloating</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Rifaximin</keyword>
</DOC>